IDEAYA Biosciences, Inc. (IDYA) is a Biotechnology company in the Healthcare sector, currently trading at $32.35. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is IDYA = $47 (+44.5% upside).
Valuation: IDYA trades at a trailing Price-to-Earnings (P/E) of -24.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.71.
Financials: revenue is $219M, +966.8%/yr average growth. Net income is $114M (loss), growing at -63.5%/yr. Net profit margin is -52% (negative). Gross margin is 97.9% (+2 pp trend).
Balance sheet: total debt is $28M against $1.0B equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 11.34 (strong liquidity). Debt-to-assets is 2.5%. Total assets: $1.1B.
Analyst outlook: 22 / 24 analysts rate IDYA as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 70/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 100/100 (Pass), Income 10/100 (Fail).
